Clinical Trials

Amgen, UCB explore option of second course of treatment with evenity

Amgen and UCB have released results from the fourth year of a Phase 2 study demonstrating the safety and efficacy of a second course of treatment with evenity (romosozumab), an investigational candidate for postmenopausal women with osteoporosis.

Ritter reports topline phase 2b/3 results for lactose intolerance treatment RP-G28

Ritter Pharmaceuticals' lactose intolerance treatment, RP-G28, demonstrated efficacy and clinically meaningful benefit in phase 2b/3 clinical trial.

Summit to extend PhaseOut DMD trial for ezutromid

Summit Therapeutics has announced that, subject to regulatory approval, it will go ahead with the planned extension phase of PhaseOut DMD, a Phase 2 clinical trial studying the utrophin modulator ezutromid.

Akashi gets FDA nod to restart clinical development of DMD drug HT-100

Akashi Therapeutics has secured approval from the US Food and Drug Administration (FDA) to resume clinical development of HT-100 (delayed-release halofuginone) in patients with any of the genetic mutations that cause Duchenne muscular dystrophy (DMD).

Lilly’s abemaciclib meets primary endpoint in phase 3 breast cancer trial

A phase 3 study of Lilly’s breast cancer drug, abemaciclib, in combination with fulvestrant, has met its primary endpoint of progression-free survival (PFS).

Nektar’s NKTR-181 shown to reduce chronic pain in phase 3 trial

Nektar Therapeutics’ NKTR-181 has met primary and secondary endpoints in phase 3 SUMMIT-07 study in chronic pain.

Novartis’ heart failure drug Entresto improves glycemic control in Phase III study

Novartis has unveiled results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes indicating that Entresto (sacubitril/valsartan) tablets enahanced glycemic control, as evaluated by hemoglobin A1c (HbA1c) testing, compared to ACE-inhibitor enalapril.

Indivior plans to file NDA for schizophrenia drug in Q4 2017

Indivior has unveield positive top-line 12-Month phase 3 results confirming long-term safety profile of RBP-7000 in patients with schizophrenia.

BerGenBio signs deal with Merck to test lung and breast cancer combo

BerGenBio has signed a collaborative agreement with Merck focused the clinical study of BGB324 with Keytruda (pembrolizumab) in patients with advanced non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).